AGP Picks
View all

AGP Executive Report

Last update: 38 minutes ago

Drinking Water: Kozloduy’s state of disaster has been extended for up to 30 days after tests still found water-quality violations. Chromium levels have fallen, but remain above the legal limit; bottled water is being supplied to childcare facilities and distribution points. Vaccination: WHO surveys found 88.4% of parents said their children had received all recommended mandatory vaccines, but HPV vaccination remains low, with many parents still undecided. Emergency Care: Bulgaria’s air ambulance service has completed 237 missions this year, including 33 in October. Police patrol cars are also due to receive defibrillators next year, with officers set to be trained to use them. Community Health: Health mediators urged Parliament to back their work sharing prevention and vaccination advice, particularly in vulnerable communities. Cost Pressures: An EIB survey found half of Bulgarians have cut spending on food or healthcare to cope with rising energy costs.

Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.

AGP Wire

fallback image
Sep. 30, 2026

James Moore hires nonprofit finance veteran Anita Bushnyakova

AGP

fallback image
Sep. 17, 2026

European malls speed up food court automation with robot kiosks

AGP

fallback image
Aug. 5, 2026

Stablepharma publishes Phase 1 data for fridge-free Td vaccine SPVX02

AGP


Perspectify logo Perspectify News

Learn about labels.

Labels
Left-wing Center-left Neutral Public Broadcaster Gov't Institution Center-right Right-wing Pro-Government Gov't Propaganda Indeterminate Press Release Service
filter

Filter

Source Label Filters

All labels are selected. Deselect any labels you want to hide from your feed.

Labels:

Left-wing
Center-left
Neutral
Public Broadcaster
Gov't Institution
Center-right
Right-wing
Pro-Government
Gov't Propaganda
Indeterminate
Press Release Service

fallback image
Oct. 30, 2026

Aer Therapeutics Announces Top-Line Results from its Phase 2a Proof-of-Concept Trial of Fexlamose in Chronic Obstructive Pulmonary Disease (“COPD”)

GlobeNewswire, Inc.

fallback image
Sep. 30, 2026

Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026

GlobeNewswire, Inc.

fallback image
Sep. 9, 2026

Discovering the Formula for Health in Yogurt: 9th Bright Dairy Yogurt Cultural Festival Concludes in Bulgaria

GlobeNewswire, Inc.

fallback image
Aug. 25, 2026

Nika Pharmaceuticals, Inc. (OTCQB: NIKA) Funding Update

GlobeNewswire, Inc.

fallback image
Nov. 3, 2026

EIMA 2026 draws Brazilian manufacturers as agricultural machinery exports to Europe rise 13%

EIN Presswire

More press releases

Video Stories

YouTube video thumbnail: Europe Is Betting €525 Million on Chip Design Start-Ups
Play
Europe Is Betting €525 Million on Chip Design Start-Ups
YouTube video thumbnail: Why Are Airports Across Europe Receiving Hoax Bomb Threats?
Play
Why Are Airports Across Europe Receiving Hoax Bomb Threats?
YouTube video thumbnail: Discover Affinity Group Publishing
Play
Discover Affinity Group Publishing
YouTube video thumbnail: Leaders Meet for COP31 Climate Talks After a Year of Disasters and Energy Shocks
Play
Leaders Meet for COP31 Climate Talks After a Year of Disasters and Energy Shocks
YouTube video thumbnail: China Threatens EU With Retaliation As EU Mulls “Kill-Switch” to Defend its Market
Play
China Threatens EU With Retaliation As EU Mulls “Kill-Switch” to Defend its Market

Video Title

Sign up for:

Wellness Daily Bulgaria

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

globe

Explore More

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Wellness Daily Bulgaria

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.